Track topics on Twitter Track topics that are important to you
Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.
CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. (www.neuronascent.com), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today annou...
DelveInsight's, Brain Ischemia Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Brain Ischemia. The key objective of the report is to establish the und...
Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, n...
Neuronascent began operations in a fully functional cell culture facility in Maryland. Neuronascent is in the process of developing small-molecule therapeutics for Alzheimer’s disease and depression...
We have published hundreds of Neuronascent, Inc. news stories on BioPortfolio along with dozens of Neuronascent, Inc. Clinical Trials and PubMed Articles about Neuronascent, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neuronascent, Inc. Companies in our database. You can also find out about relevant Neuronascent, Inc. Drugs and Medications on this site too.
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...